{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T06:50:15Z","timestamp":1765608615269},"publisher-location":"New York, NY","reference-count":27,"publisher":"Springer New York","isbn-type":[{"type":"print","value":"9781493978151"},{"type":"electronic","value":"9781493978168"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/978-1-4939-7816-8_28","type":"book-chapter","created":{"date-parts":[[2018,6,9]],"date-time":"2018-06-09T13:06:41Z","timestamp":1528549601000},"page":"463-470","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Quantitative Metabolomics in Alzheimer\u2019s Disease: Technical Considerations for Improved Reproducibility"],"prefix":"10.1007","author":[{"given":"Sergio","family":"Veiga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Wahrheit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Rodr\u00edguez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Sonntag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,8]]},"reference":[{"key":"28_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/alzrt164","volume":"5","author":"D Galasko","year":"2013","unstructured":"Galasko D, Golde TE (2013) Biomarkers for Alzheimer\u2019s disease in plasma, serum and blood - conceptual and practical problems. Alzheimers Res Ther 5:10","journal-title":"Alzheimers Res Ther"},{"key":"28_CR2","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3233\/JAD-142925","volume":"45","author":"J Olazaran","year":"2015","unstructured":"Olazaran J, Gil-de-Gomez L, Rodriguez-Martin A et al (2015) A blood-based, 7-metabolite signature for the early diagnosis of Alzheimer\u2019s disease. J Alzheimers Dis 45:1157\u20131173","journal-title":"J Alzheimers Dis"},{"key":"28_CR3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3389\/fneur.2015.00237","volume":"6","author":"MS Fiandaca","year":"2015","unstructured":"Fiandaca MS, Zhong X, Cheema AK et al (2015) Plasma 24-metabolite panel predicts preclinical transition to clinical stages of Alzheimer\u2019s disease. Front Neurol 6:237","journal-title":"Front Neurol"},{"key":"28_CR4","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jalz.2015.12.008","volume":"12","author":"R Casanova","year":"2016","unstructured":"Casanova R, Varma S, Simpson B et al (2016) Blood metabolite markers of preclinical Alzheimer\u2019s disease in two longitudinally followed cohorts of older individuals. Alzheimers Dement 12:815\u2013822","journal-title":"Alzheimers Dement"},{"key":"28_CR5","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nm.3466","volume":"20","author":"M Mapstone","year":"2014","unstructured":"Mapstone M, Cheema AK, Fiandaca MS et al (2014) Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 20:415\u2013418","journal-title":"Nat Med"},{"key":"28_CR6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jalz.2016.08.003","volume":"13","author":"P Proitsi","year":"2017","unstructured":"Proitsi P, Kim M, Whiley L et al (2017) Association of blood lipids with Alzheimer\u2019s disease: a comprehensive lipidomics analysis. Alzheimers Dement 13:140\u2013151","journal-title":"Alzheimers Dement"},{"key":"28_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s11306-007-0082-2","volume":"3","author":"LW Sumner","year":"2007","unstructured":"Sumner LW, Amberg A, Barrett D et al (2007) Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics 3:211\u2013221","journal-title":"Metabolomics"},{"issue":"5","key":"28_CR8","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1351\/pac200274050835","volume":"74","author":"Michael Thompson","year":"2002","unstructured":"Thompson M (2002) Harmonized guidelines for single laboratory validation of methods of analysis (IUPAC Technical Report). Pure Appl Chem 74: n\u00ba5, pp 835\u2013855.","journal-title":"Pure and Applied Chemistry"},{"key":"28_CR9","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2165\/00023210-200317090-00004","volume":"17","author":"DA Butterfield","year":"2003","unstructured":"Butterfield DA, Pocernich CB (2003) The glutamatergic system and Alzheimer\u2019s disease: therapeutic implications. CNS Drugs 17:641\u2013652","journal-title":"CNS Drugs"},{"key":"28_CR10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/BF02252924","volume":"2","author":"H Basun","year":"1990","unstructured":"Basun H, Forssel LG, Almkvist O et al (1990) Amino acid concentrations in cerebrospinal fluid and plasma in Alzheimer\u2019s disease and healthy control subjects. J Neural Transm Park Dis Dement Sect 2:295\u2013304","journal-title":"J Neural Transm Park Dis Dement Sect"},{"key":"28_CR11","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.bbadis.2013.09.010","volume":"1842","author":"RH Swerdlow","year":"2014","unstructured":"Swerdlow RH, Burns JM, Khan SM (2014) The Alzheimer\u2019s disease mitochondrial cascade hypothesis: progress and perspectives. Biochim Biophys Acta 1842:1219\u20131231","journal-title":"Biochim Biophys Acta"},{"key":"28_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1743-7075-6-31","volume":"6","author":"ST Henderson","year":"2009","unstructured":"Henderson ST, Vogel JL, Barr LJ et al (2009) Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer\u2019s disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond) 6:31","journal-title":"Nutr Metab (Lond)"},{"key":"28_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021643","volume":"6","author":"X Han","year":"2011","unstructured":"Han X, Rozen S, Boyle SH et al (2011) Metabolomics in early Alzheimer\u2019s disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One 6:e21643","journal-title":"PLoS One"},{"key":"28_CR14","first-page":"295","volume":"1","author":"K Klavins","year":"2015","unstructured":"Klavins K, Koal T, Dallmann G et al (2015) The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer\u2019s disease and mild cognitive impairment. Alzheimers Dement 1:295\u2013302","journal-title":"Alzheimers Dement"},{"key":"28_CR15","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.3233\/JAD-142319","volume":"44","author":"T Koal","year":"2015","unstructured":"Koal T, Klavins K, Seppi D et al (2015) Sphingomyelin SM(d18:1\/18:0) is significantly enhanced in cerebrospinal fluid samples dichotomized by pathological amyloid-beta42, tau, and phospho-tau-181 levels. J Alzheimers Dis 44:1193\u20131201","journal-title":"J Alzheimers Dis"},{"key":"28_CR16","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1016\/j.jalz.2013.12.010","volume":"10","author":"ST Ferreira","year":"2014","unstructured":"Ferreira ST, Clarke JR, Bomfim TR et al (2014) Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer\u2019s disease. Alzheimers Dement 10:S76\u2013S83","journal-title":"Alzheimers Dement"},{"key":"28_CR17","first-page":"1","volume":"6","author":"D Li","year":"2017","unstructured":"Li D, Misialek JR, Boerwinkle E et al (2017) Prospective associations of plasma phospholipids and mild cognitive impairment\/dementia among African Americans in the ARIC Neurocognitive Study. Alzheimers Dement 6:1\u201310","journal-title":"Alzheimers Dement"},{"key":"28_CR18","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.jalz.2017.01.020","volume":"3","author":"JB Toledo","year":"2017","unstructured":"Toledo JB, Arnold M, Kastenmuller G et al (2017) Metabolic network failures in Alzheimer\u2019s disease-A biochemical road map. Alzheimers Dement 3:965\u2013984","journal-title":"Alzheimers Dement"},{"key":"28_CR19","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jalz.2014.08.099","volume":"11","author":"SE O'Bryant","year":"2015","unstructured":"O'Bryant SE, Gupta V, Henriksen K et al (2015) Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer\u2019s disease research. Alzheimers Dement 11:549\u2013560","journal-title":"Alzheimers Dement"},{"key":"28_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135437","volume":"10","author":"M Carayol","year":"2015","unstructured":"Carayol M, Licaj I, Achaintre D et al (2015) Reliability of serum metabolites over a two-year period: a targeted metabolomic approach in fasting and non-fasting samples from EPIC. PLoS One 10:e0135437","journal-title":"PLoS One"},{"key":"28_CR21","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1373\/clinchem.2012.199257","volume":"59","author":"P Yin","year":"2013","unstructured":"Yin P, Peter A, Franken H et al (2013) Preanalytical aspects and sample quality assessment in metabolomics studies of human blood. Clin Chem 59:833\u2013845","journal-title":"Clin Chem"},{"key":"28_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089728","volume":"9","author":"M Breier","year":"2014","unstructured":"Breier M, Wahl S, Prehn C et al (2014) Targeted metabolomics identifies reliable and stable metabolites in human serum and plasma samples. PLoS One 9:e89728","journal-title":"PLoS One"},{"key":"28_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021103","volume":"6","author":"A Floegel","year":"2011","unstructured":"Floegel A, Drogan D, Wang-Sattler R et al (2011) Reliability of serum metabolite concentrations over a 4-month period using a targeted metabolomic approach. PLoS One 6:e21103","journal-title":"PLoS One"},{"key":"28_CR24","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jalz.2016.11.004","volume":"13","author":"M Mapstone","year":"2017","unstructured":"Mapstone M, Cheema AK, Zhong X et al (2017) Biomarker validation: methods and matrix matter. Alzheimers Dement 13:608\u2013609","journal-title":"Alzheimers Dement"},{"key":"28_CR25","unstructured":"Ramsay SL, Stoeggl WM, Weinberger KM, Graber A, Guggenbichler W (Inventors). Biocrates Life Sciences AG (Assignee). Apparatus and method for analyzing a metabolite profile. US Patent 20070004044. Published 04 Jan 2007. 27"},{"key":"28_CR26","unstructured":"Ramsay SL, Guggenbichler W, Weinberger KM, Graber A, Stoeggl WM (Inventors). Biocrates Life Sciences AG (Assignee). Device for quantitative analysis of a drug or metabolite profile. US Patent 20070003965. Published 04 Jan 2007"},{"key":"28_CR27","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1021\/acs.analchem.6b02930","volume":"89","author":"AP Siskos","year":"2017","unstructured":"Siskos AP, Jain P, Romisch-Margl W, Bennett M, Achaintre D, Asad Y, Marney L, Richardson L, Koulman A, Griffin JL, Raynaud F, Scalbert A, Adamski J, Prehn C, Keun HC (2017) Interlaboratory reproducibility of a targeted metabolomics platform for analysis of human serum and plasma. Anal Chem 89:656\u2013665","journal-title":"Anal Chem"}],"container-title":["Methods in Molecular Biology","Amyloid Proteins"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-7816-8_28","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,6,9]],"date-time":"2018-06-09T13:10:00Z","timestamp":1528549800000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-7816-8_28"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9781493978151","9781493978168"],"references-count":27,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-7816-8_28","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2018]]}}}